ABSTRACT-We investigated the effect of propylidene]-6,11-dihydro dibenz [b,e]oxepin-2-acetic acid monohydrochloride), an orally active anti-allergic drug, on antigen-in duced airway hyperresponsiveness using two different indicators, pulmonary resistance (RL) and dynamic lung compliance (Cdyn), in actively sensitized guinea pigs. Oral administration of KW-4679 (0.1 and 1 mg/kg) 1 hr before aerosolized antigen exposure significantly inhibited the development of airway hyper responsiveness to inhaled acetylcholine in RL and Cdyn in a dose-dependent manner. Terfenadine (10 mg/kg) also inhibited the development of airway hyperresponsiveness. These results indicate that KW-4679 could be useful in the treatment of bronchial asthma.
Airway hyperresponsiveness (AHR) is one of the most important pathophysiological features of asthma. Ac cordingly, it is very essential to find a way to alleviate the AHR. To date, virus (1)-, ozone (2)-, platelet activating factor (PAF) (3)-, lipopolysaccharide (4) and antigen (5) induced AHR models in various animals are widely used in many laboratories. The model of antigen-induced AHR in particular is an essential model for evaluating the efficacy of drugs.
KW-4679 ((Z)-11-[(3-dimethylamino)propylidene]-6,11 dihydrodibenz[b,e]oxepin-2-acetic acid monohydrochlo ride) is an orally active anti-allergic drug that inhibits both the release and the action of histamine (6, 7) . KW-4679 also inhibits the production and/or release of PAF and leukotriene B4 (LTB4) in human neutrophils (8) . KW-4679 reduces the electrical field stimulation induced tachykininergic contraction through reduction in the release of transmitters from sensory nerve endings in the isolated guinea pig main bronchus (9) . Receptor binding studies have shown this compound to be a hista mine H1-receptor antagonist with a K; value of 16 nM (10). KW-4679 had neither anti-cholinergic, ganglion blocking, a-adrenergic blocking nor ~-adrenergic recep tor stimulating properties.
In the present study, we investigated the effect of KW Active sensitization and antigen exposure were per formed as previously described by Boichot et al. (5) , with a slight modification. For active sensitization, male Hart ley guinea pigs (Charles River, Yokohama), weighing 350 to 500 g, were exposed twice for 30 min to an aerosol of 0.2% ovalbumin (OA, chicken egg, grade III; Sigma, St. Louis, MO, USA) at a 48-hr interval in a plastic chamber (30 x 50 x 30 cm). The aerosol was generated by an ultra sonic nebulizer (Ultra-NEB 99; DeVilbiss, Sommerset, PA, USA). Under these conditions, the aerodynamic diameter of the nebulized particles was between 0.5 and 3 pm. At 15 20 days after the initial sensitization pro cedure, the guinea pigs were challenged in the plastic chamber as described above by exposure to aerosols of five successive increasing concentrations of OA (0.01, 0.1, 0.5, 1 and 5 mg/ml) for 15 min each. One hour after the last challenge with the highest concentration of OA, no apparent sign of respiratory failure was observed in the guinea pigs.
KW-4679, which was synthesized in our laboratories, was dissolved in distilled water. Terfenadine (Sigma), which is a non-sedative histamine H1 antagonist, was sus pended in 0.3% carboxymethylcellulose (CMC) solution. Drugs were administered orally 1 hr before the first anti gen challenge. As a vehicle-treated group, sensitized guinea pigs were administered distilled water or 0.3% CMC solution instead of drugs.
Twenty-four hours after the antigen challenge, the guinea pigs were anesthetized with urethane (1.2 g/kg, i.p.; Tokyo Kasei Kogyo, Tokyo) and artificially venti lated by a respiratory pump (Ugo Basile, Varese, Italy) with a constant volume of 1 ml laboratory air/ 100 g body weight at 60 breaths/min. Spontaneous breathing was abolished by injection of gallamine triethiodide (Sigma, 3 mg/animals) into the jugular vein. After a sufficient stabilization period, five successive 1-min aerosol ad ministrations of acetylcholine chloride (ACh; Daiichi Pharmaceutical Co., Ltd., Tokyo; 20, 50, 100, 150 and 200 pg/ml) were performed. The aerosol was generated by an ultrasonic nebulizer connected to the inspiratory line of the respiratory pump using three-way breathing valves. The airflow signal and the pressure signal meas ured by pressure transducers were electronically inte grated using a computerized pulmonary function moni toring system (Model 6; Buxco Electronics, Sharon, CT, USA). RL and Cdyn were simultaneously calculated by this system according to the method of Aoki et al. (11) . First, the following four groups were examined: unsen sitized and saline-challenged animals (saline-saline), un sensitized and OA-challenged animals (saline-OA), sensi tized and saline-challenged animals (OA-saline) and sen sitized and OA-challenged animals (OA-OA). The groups of unsensitized animals and saline-challenged animals were exposed to saline instead of OA under the same conditions in the sensitization procedure and in the challenge procedure, respectively. Inhalation of ACh produced a concentration-dependent increase in RL and reduction in Cdyn (Fig. 1) . In the group of OA-OA, the AHR to ACh was clearly observed; that is, the alterations in both RL and Cdyn were significantly enhanced at 20, 50 and 100 pg/ml of ACh compared to the other groups. In contrast, no significant alterations were observed in both RL and Cd,,n at each concentration of ACh between the groups of saline-saline, saline-OA and OA-saline. In ad dition, there were slight but significant reductions in the basal Cdyn values measured just before ACh exposure in the group of OA-OA.
The oral treatment of 0.1 and 1 mg/kg of KW-4679 1 hr before antigen challenge significantly prevented the de velopment of AHR (Fig. 2) . A significant inhibition was observed in RL in a dose-dependent manner. In the ex periment on the OA-saline group, treatment of 1 mg/kg of KW-4679 1 hr before the saline challenge almost never influenced the airway responsiveness to ACh in both RL and Cdyn (data not shown). It is therefore considered that the alterations of airway responsiveness caused by pretreatment of KW-4679 were due to the prevention of the development of AHR, not a bronchodilative action or an anti-cholinergic action. The oral pretreatment of 10 mg/kg of terfenadine also significantly inhibited the de velopment of AHR (Fig. 3) . In a recent study, Mauser et al. (12) reported that bronchoscopy at 24 hr after antigen challenge showed clear signs of inflammation in peripheral airways such as tissue edema and hyperemia. Moreno et al. (13) demon strated by morphological and physiological studies that airway wall thickness is one of the mechanisms of the de velopment of AHR. We also observed a significant base line reduction in Cdyn. Accordingly, it is likely that suc cessive antigen exposures induce the development of AHR through the manifestation of edema in peripheral airways, although it has not been fully elucidated. It has been demonstrated that a variety of mediators such as thromboxanes (TXs), leukotrienes, PAF and tachykinins participate in the development of AHR.
Recently, Santing et al. (14) reported that histamine may contribute to the antigen-induced AHR in guinea pigs. The development of AHR, not surprisingly, was marked ly reduced by drugs that inhibit both the release and the action of histamine. It is therefore likely that the inhibi tory effect of drugs such as KW-4679 and terfenadine on the development of AHR is based on their anti-histaminic properties. We also found that KW-4679 (1 mg/kg, p.o.) inhibited the production and/or release of TXB2 from leukocytes in bronchial alveolar lavage fluid of guinea pigs (Y. Sasaki, unpublished data). On the other hand, we recently demonstrated that KW-4679 inhibits the an tigen-induced development of AHR through the preven tion of eosinophil infiltration into guinea pig airways using a mild-symptoms experimental model that utilizes a single-antigen challenge with metyrapone (15) . Conse quently, although the anti-asthmatic mechanism of KW 4679 has not been fully elucidated, it is considered that not only the inhibition of leukocyte infiltration but also the prevention of the action of chemical mediators (e.g., edema formation) such as TXA2, LTB4, PAF, tachykinins and especially histamine could contribute to the inhibi tory effect of KW-4679 on the development of AHR.
In conclusion, we demonstrated that pretreatment by the oral administration of KW-4679 markedly inhibited the development of AHR elicited by the successive anti gen challenge in actively sensitized guinea pigs. These findings suggest that KW-4679 will be beneficial for the treatment of bronchial asthma.
